Viking Therapeutics: 'Strong Buy' On Injectable VK2735 Maintenance Data And Treatment Optionality

Viking Therapeutics maintains a 'Strong Buy' rating, driven by positive phase 2 and maintenance data for its dual GLP-1/GIP agonist VK2735 in obesity. VKTX is advancing both injectable [SC] and oral VK2735, with phase 3 SC studies ongoing and phase 3 oral studies expected to initiate in Q4 2026. SC VK2735 demonstrated robust maintenance of weight loss—97% with every-other-week and 90% with monthly dosing—highlighting differentiation potential versus competitors.

VKTX has $502M cash but may need to raise additional funds within the next year, leveraging an existing $500M ATM facility if necessary.